

Pharmacy Prior Authorization Form

For Prior Authorization, please fax to: 877 974-4411 toll free, or 616 942-8206

This form applies to: **Commercial (Traditional)** **Commercial (Individual/Optimized)**

Medicaid

This request is: **Urgent** (life threatening) **Non-Urgent** (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

Abstral[®] (fentanyl citrate sublingual tablet)

Member

Last Name: _____

First Name: _____

ID #: _____

DOB: _____ Gender: _____

Primary Care Physician: _____

Requesting Provider: _____

Prov. Phone: _____ Prov. Fax: _____

Provider Address: _____

Provider NPI: _____

Contact Name: _____

Provider Signature: _____

Date: _____

Product Information

New request Continuation request

Drug product:

- Abstral 100 mcg tablet
- Abstral 200 mcg tablet
- Abstral 300 mcg tablet
- Abstral 400 mcg tablet
- Abstral 600 mcg tablet
- Abstral 800 mcg tablet

Start date (or date of next dose): _____

Date of last dose (if applicable): _____

Dosing frequency: _____

Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

1. This drug is being used to manage breakthrough pain in cancer patients already receiving and tolerant to around-the-clock opioid therapy for persistent cancer pain
2. Age 18 or older

Note: Patients are considered opioid tolerant when taking oral morphine 60 mg/day or more, transdermal fentanyl 25 mcg/hr, oral oxycodone 30 mg/day, oral hydromorphone 8 mg/day, oral oxymorphone 25 mg/day, oral hydrocodone 60mg/day, or an equianalgesic dose of another opioid for 1 week or longer.

Note: Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

Priority Health Precertification Documentation

1. What condition is this drug being requested for?

Breakthrough cancer pain

Cancer diagnosis: _____

Other – the patient’s condition is: _____

Rationale for use: _____

2. What is the patient’s current opioid treatment (must be around-the-clock opioids for persistent cancer pain):

Drug	Dose	Dates
_____	_____	_____
_____	_____	_____
_____	_____	_____

3. What other breakthrough pain medications have been tried?

Drug	Dose	Dates
_____	_____	_____
_____	_____	_____
_____	_____	_____

4. Please provide other rationale for use, if necessary:
